etoposide has been researched along with Lung Adenocarcinoma in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SB; Gu, LQ; Huang, SL; Huang, ZH; Huang, ZS; Li, D; Ou, JB; Ou, TM; Shen, LL; Tan, JH; Wu, WB | 1 |
| Li, L; Liu, J; Luo, F; Qu, Z; Zhou, Q; Zhu, L | 1 |
| Hara, S; Hata, A; Komatsu, M; Ninomaru, T | 1 |
| Bal, A; Gupta, N; Gupta, P; Khosla, D; Shastri, M; Singh, N; Srinivasan, R | 1 |
| Li, S; Li, Z; Liu, S; Wang, Z; Zhao, F | 1 |
| Barberi-Heyob, M; Frochot, C; Jouan-Hureaux, V; Lirdprapamongkol, K; Niamsiri, N; Pramual, S; Svasti, J | 1 |
| Andrade, CF; Figueiró, F; Filippi-Chiela, E; Gonzalez, EA; Klamt, F; Nunes, V; Pilar, ES; Solari, JIG | 1 |
| Chen, L; Cheng, L; Liang, X; Liu, L; Ma, C; Wu, X; Xiao, L; Xu, Q; Zhang, L | 1 |
| Cha, HJ; Go, YH; Hong, SK; Kwon, OS; Kwon, SJ; Oh, E | 1 |
| Gao, Y; Kardos, J; Kim, WY; Major, MB; Mutter-Rottmayer, E; Tamir, TY; Vaziri, C; Weissman, B; Yang, Y | 1 |
| Khadirnaikar, S; Kumar, P; Shukla, SK | 1 |
| Fan, D; Hu, Y; Li, S; Xiong, D; Yagüe, E; Yan, C; Yang, M; Zhang, Y; Zhou, Y | 1 |
| Choi, KH; Hwang, KE; Jeong, ET; Jung, JW; Kim, HR; Oh, SJ; Park, MJ; Shon, YJ | 1 |
| Shiau, AL; Shieh, GS; Su, BH; Tseng, YL; Wu, CL | 1 |
| Akyuz, MD; Büttner, R; Erkel, M; Florin, A; Fritz, C; Jokić, M; Klümper, N; Kümpers, C; Maintz, D; Michels, S; Nowak, M; Offermann, A; Ozretić, L; Perner, S; Persigehl, T; Reinhardt, HC; Riabinska, A; Rinneburger, M; Schmitt, A; Schumacher, B; Spiro, J; Thomale, J; Vlašić, I; Vogel, W; Welcker, D; Wittersheim, M; Wolf, J | 1 |
1 review(s) available for etoposide and Lung Adenocarcinoma
| Article | Year |
|---|---|
[MDT Treatment of Small Cell Lung Cancer Complicated with Adenocarcinoma:
A Case Report and Literature Review].
Topics: Adenocarcinoma of Lung; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2021 |
14 other study(ies) available for etoposide and Lung Adenocarcinoma
| Article | Year |
|---|---|
Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Survival; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Lung Neoplasms; Naphthoquinones; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Plasmids; Pyrans; Quinones; Sesquiterpenes; Structure-Activity Relationship; Telomerase; Topoisomerase Inhibitors | 2011 |
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carboplatin; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Etoposide; Gefitinib; Humans; Immunologic Factors; Immunotherapy; Lactic Acid; Lung Neoplasms; Prognosis; Reproducibility of Results; Tumor Microenvironment | 2022 |
Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lipids; Lung Neoplasms; Nanoparticles; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polylactic Acid-Polyglycolic Acid Copolymer; Porphyrins | 2020 |
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Apoptosis; Autophagy; Calreticulin; Carboplatin; Caspase 3; Cell Survival; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; HMGB1 Protein; Humans; Immunogenic Cell Death; Lung Neoplasms; Paclitaxel; Prognosis | 2020 |
TRIM28 knockdown increases sensitivity to etoposide by upregulating E2F1 in non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lung Neoplasms; Mice; RNA, Small Interfering; Tripartite Motif-Containing Protein 28; Xenograft Model Antitumor Assays | 2017 |
BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biphenyl Compounds; Cell Proliferation; Cell Survival; Chemoradiotherapy; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Molecular Mimicry; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; RNA Interference; Signal Transduction; Sulfonamides; Transfection; Up-Regulation | 2017 |
The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; DNA End-Joining Repair; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Radiation, Ionizing; Recombinational DNA Repair | 2018 |
PILAR1, a novel prognostic LncRNA, reveals the presence of a unique subtype of lung adenocarcinoma patients with KEAP1 mutations.
Topics: A549 Cells; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Kelch-Like ECH-Associated Protein 1; Male; Mutation; Prognosis; RNA, Long Noncoding; Sequence Analysis, RNA; Survival Analysis; Up-Regulation | 2019 |
Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aldehyde Dehydrogenase 1 Family; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calcium-Binding Proteins; CD24 Antigen; Cell Movement; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Female; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Isoenzymes; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Retinal Dehydrogenase; RNA Interference; RNA, Small Interfering; Spheroids, Cellular; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2014 |
Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Remission Induction; Small Cell Lung Carcinoma | 2015 |
Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Chemotherapy, Adjuvant; E2F1 Transcription Factor; Etoposide; Feasibility Studies; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; HEK293 Cells; Homeostasis; Host-Pathogen Interactions; Humans; Lung Neoplasms; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Oncolytic Virotherapy; Oncolytic Viruses; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Time Factors; Transcription, Genetic; Transfection; Virus Replication; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2015 |
Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Proliferation; Cell Survival; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Etoposide; Humans; Lung Neoplasms; Mice; Mutation; Precision Medicine; Proto-Oncogene Proteins p21(ras); Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2016 |